Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Colesevelam Hydrochloride Tablets, 625 mg, the generic version of Welchol Tablets, 625 mg, of Daiichi Sankyo. The company has already commenced supplies of the product to the US market.
According to IQVIA sales data for the 12 month period ending March 2018, Welchol Tablets, 625 mg market achieved annual sales of approximately $519.9 million.
Glenmark’s current portfolio consists of 135 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: